3 C
New York

Japan’s AnGes speeds towards 2021 rollout in coronavirus ‘vaccine war’

Must read

Mike’s Baseline Trick? Don’t panic – a new baseline for global temperature may cool future debate – Watts Up With That?

Statistical politics – Prof. Mike Hulme on ‘politically charged’ climate baseline changes from 1961-1990 to 1991-2020:‘In an instant; today, the world’s climate has...

Snapchat Wants You to Article. They are Prepared to Pay Thousands and thousands.

In late November, Cam Casey, a TikTok star with over 7 million followers, was comforting at dwelling when he determined to upload a video...

Eliminate the literacy check from the NC Structure

When the 2021-2022 session of the North Carolina Typical Assembly begins do the job, legislators will facial area no lack of urgent difficulties. Coronavirus...

By Rocky Swift

OSAKA, June 10 (Reuters) – Japanese biotech AnGes Inc expects its coronavirus vaccine to be ready as early as the first half of 2021, if it can overcome supply chain and production hurdles, the company’s founder said.

The Osaka-based firm had a headstart in the potential COVID-19 vaccine development by repurposing its hypertension vaccine that had already passed through high safety and regulatory standards and other hurdles.

Ryuichi Morishita told Reuters that Japan’s health ministry and Pharmaceuticals and Medical Devices Agency “already had strong confidence in our product” because of that experience.

The comments come as Japan’s government has earmarked $1.3 billion in its latest budget for vaccine production as it seeks to put the coronavirus vaccine into use and hopes to host a delayed Tokyo Olympics next year.

Drugmakers around the world are scrambling to develop treatments and vaccines for COVID-19, the respiratory disease caused by the highly infectious new coronavirus which has so far killed more than 400,000 people worldwide.

There are 10 vaccines in clinical trials and dozens more in pre-clinical evaluation, according to the World Health Organization, but mass production and allocation remain significant challenges.

Morishita also warned that shortages in everything from drug compounds to glass vials, as hundreds of institutes and companies carry out research simultaneously, have emerged in what he calls a “vaccine war” and could complicate production.

AnGes’s candidate is one of Japan’s best hopes at a coronavirus vaccine, as development is further along than some being produced by other firms such as Shionogi & Co and Daiichi Sankyo Co.

The AnGes candidate is a plasmid DNA vaccine that disables the connection between the protein spikes of the coronavirus and receptors in human cells.

Early results from tests in mice show increased antibody production, and tests in 30 human volunteers are due to begin in July, with first results expected in September.

By contrast, other candidates such as U.S. firm Moderna Inc’s vaccine are based on messenger RNA (mRNA) that instructs human cells to make specific coronavirus proteins that produce an immune response. Other varieties are based on inactivated forms of the virus.

Morishita, who launched AnGes 20 years ago out of Osaka University, has seen the company’s market valuation surge more than five fold to $2.4 billion since it announced its coronavirus campaign in March.

“The future of COVID-19 is very mysterious,” said Morishita, adding that any vaccine would likely need constant tweaking as the virus mutates and returns. (Reporting by Rocky Swift; Editing by Miyoung Kim and Ana Nicolaci da Costa)

Source link

Some Exciting Offer For You

More articles

LEAVE A REPLY

Please enter your comment!
Please enter your name here

65 + = 69

Latest article

Mike’s Baseline Trick? Don’t panic – a new baseline for global temperature may cool future debate – Watts Up With That?

Statistical politics – Prof. Mike Hulme on ‘politically charged’ climate baseline changes from 1961-1990 to 1991-2020:‘In an instant; today, the world’s climate has...

Snapchat Wants You to Article. They are Prepared to Pay Thousands and thousands.

In late November, Cam Casey, a TikTok star with over 7 million followers, was comforting at dwelling when he determined to upload a video...

Eliminate the literacy check from the NC Structure

When the 2021-2022 session of the North Carolina Typical Assembly begins do the job, legislators will facial area no lack of urgent difficulties. Coronavirus...

Central Bank Digital Currencies Not a ‘Fad,’ MetLife Investment Says

The investment giant predicts CBDCs will continue gaining steam, although a "launch among Western countries seems unlikely to occur anytime soon."Source link